European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastic agents - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy.in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).

Israel - English - Ministry of Health

sanofi israel ltd - isatuximab - concentrate for solution for infusion - isatuximab 20 mg / 1 ml - isatuximab - sarclisa is indicated:- in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).- in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - isatuximab - infusion, solution concentrate - isatuximab 20mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - isatuximab, quantity: 500 mg - injection, concentrated - excipient ingredients: water for injections; histidine hydrochloride monohydrate; sucrose; polysorbate 80; histidine - sarclisa is indicated:,? in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).,? in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - isatuximab, quantity: 100 mg - injection, concentrated - excipient ingredients: histidine; histidine hydrochloride monohydrate; polysorbate 80; sucrose; water for injections - sarclisa is indicated:,? in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).,? in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.